Successful UK Launch of Mast Uri®System
Urinary tract infections (UTIs) are one of the most common infectious diseases in healthcare settings, and account for up to 65% of the laboratory work load. Using laborious standard methods, it can take from 48 - 96 hours for a result to be generated leading to a delayed or erroneous identification, which is particularly concerning for complicated infections where rapid reporting of results is imperative.
The Mast Uri®System permits around 95% of all urines to be processed in 24 hours inclusive of an antibiotic susceptibility result and organism identification.
The Mast Uri®System encompasses the Mast Uri® Plus analyser, Mast Uri® Well dispensing aid, Mast Uri® Plates and Mast Uri® Dot inoculator with 96-well head and pins to deliver results in a fast and cost effective manner.
The application of EUCAST defined breakpoints and expert rules permit accurate bacterial identification and antibiotic susceptibility results assisting the reliable reporting of intrinsic resistances and exceptional phenotypes.
A validation trial completed by GSTS Pathology department, St Thomas Hospital, London, highlighted a considerable reduction in result turnaround time; follow up work and total processing time. Other major benefits included a potential to increase capacity by 3 x workload, cost savings of bio-hazardous waste disposal, and 'freed up' valuable fridge and incubator space due to the 96-well format of the Mast Uri® Plates.
To view a full version of the poster click here.
Mast is announcing the international launch of the Mast Uri®System at ECCMID from 31st March to 3rd April 2012 in London. Visitors to the Mast stand will have an opportunity to view the Simple, Efficient, Effective solution to urine microbiology.
Tags: Identification, Pathogen
Date Published: February 2, 2012
Source article link: Mast Group » company contact details
Why Bio-Rad? Learn More Here!
CE Marking for Micro-Dx™ - Automated Direct Pathogen Diagnosis
Explore Charles River Microbial Solutions Extensive QC Micro Portfolio
12th Annual PDA Global Conference on Pharmaceutical Microbiology
Hygiena Expands Testing Portfolio to Cover Entire Contamination Detection Spectrum